Clinical Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: heart | prostate cancer | prostate | cardiovascular
  • Age: Between 18 - 90 Years
  • Gender: Male

Other eligibility criteria:

 *If you plan to father a child, you should not participate in this trial since the risks associated with sperm exposure to FIRMAGON or LUPRON have not been evaluated. The trial doctor may discuss acceptable forms of birth control with you. If you think your partner is pregnant during the trial, you must tell the trial doctor immediately. You must also not donate sperm during the trial and for at least 4 weeks after completion of the trial.

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu